🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to scientists.

An International Public Health Issue

The sexually transmitted infection are on the rise worldwide, with data suggesting more than 82 million new cases per year. Especially elevated rates are reported in the African continent and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary step in the reality of growing infection rates, escalating drug resistance and the highly restricted therapeutic options at this time.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has designated it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for use against gonorrhoea. This STI can lead to major issues, including the inability to conceive. Scientists believe that specific application of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in concurrent days. This treatment, which is employed against UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP collaborated with the drug firm its industry partner to see it through.

“This approval signifies a major breakthrough in the therapy of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Research Study Outcomes and Global Access

According to data detailed in a major medical journal, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This establishes an equal footing with the current standard treatment, which combines an injection and a pill. The trial enrolled hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the authority to make available and distribute the drug in many developing nations.

Clinicians on the front lines have expressed positive views. Having a one-pill regimen like this is seen as a "game-changer" for gonorrhoea control. This is deemed crucial to reduce the burden of the infection for patients and to halt the transmission of extremely resistant gonorrhoea around the world.